Emyria advances national expansion via reimbursed Empax Clinic network

Emyria has today released its Quarterly Activities and Cash Flow Report for the period ending 31 December 2025, highlighting a quarter of continuing clinical expansion for the Company.  

Key highlights for the period include:  

• Strong revenue growth with group company revenue of ~$892,000 for the period reflecting continued Empax clinic growth. 

• National Empax clinic network established with clinics operating or secured across Victoria, Western Australia and Queensland.  

• First Victorian Empax clinic secured at Avive Health’s Mornington Peninsula mental-health hospital.  

• Institutional placement completed – $8.0 million raised from specialist life-sciences and healthcare aligned institutional investors. 

• Dual reimbursement pathways active with private health insurer (Medibank) and government payer (Department of Veterans’ Affairs) funding now possible. 

• Perth Clinic capacity expanded with additional treatment rooms approved, therapist and authorised prescriber capacity increased. 

• First insurer-funded patients treated at the Brisbane Empax clinic.  

• Exclusive rights secured to roll out Empax clinics across all Avive Health sites across multiple states. 

Emyria Executive Chairman, Greg Hutchinson, commented: 

“The December quarter represented a defining step forward for Emyria as we moved distinctly from early validation to national execution. With Empax clinics now operating or secured across Western Australia, Queensland and Victoria, dual reimbursement pathways active, and a strengthened balance sheet following our institutional placement, the foundations for scalable growth are firmly in place. 

“Perth continues to operate as Emyria’s reference clinic, with growing utilisation. Brisbane has successfully demonstrated we can operate in multiple states, and we have secured our first Victorian clinic. As we move through CY2026, our focus is firmly on activating more clinics, increasing treatment bed capacity, enhancing reimbursed patient volumes, and importantly, improving patient outcomes.” 

Click to read the ASX release.